KA/EN
Register
Medicines reference
Search
Search
Product

Cipro-Denk

Favourites

Ciprofloxacin · Denk Pharma

2 forms: coated tablet. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form Dose Frequency Georgia
500 mg, Coated tablet No label dose in the reference yet - Georgia Yes, human
In force until 22 Jun 2028
Human (Ministry of Health, RAMA)
№ რ-038444
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Cipro-Denk 500 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.4/10
Weak evidence support
vetman assessment

Cipro-Denk

500 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 5.4/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-038444 · Verified on 15 Oct 2026 Off-label use

A weak reserve option rather than a routine veterinary fluoroquinolone. Even within this specialist-directed scope, oral tablet exposure is unpredictable and meaningful ciprofloxacin susceptibility interpretation and effective canine dosing are not established; prefer a licensed, better-characterised alternative whenever possible.

Regulatory and scientific credibility6.0/10

This exact human tablet family has a sourced current Georgian registration, identifiable official manufacturer information and exact regulator-hosted product information, but no exact EU/EEA, GB or US registration in the checked registers. Animal use is off-label.

Clinical efficacy4.0/10

Ciprofloxacin has concentration-dependent activity against selected susceptible bacteria, but current ISCAID guidance excludes oral ciprofloxacin from canine pyoderma choices: tablet absorption is low and highly variable, veterinary susceptibility breakpoints are unavailable and an effective canine dose is not established. Urinary guidance also finds it difficult to justify over approved veterinary fluoroquinolones.

Safety and tolerability5.5/10

Gastrointestinal and CNS effects, dysglycaemia, hypersensitivity, QT/tendon risks, renal clearance and drug-chelation interactions are clinically relevant; immature animals are vulnerable to quinolone arthropathy. Correctly selected adult dogs can tolerate fluoroquinolones, but exact-product veterinary safety and dosing-margin data are absent.

Clinical practicality6.5/10

The scored 500 mg tablet can be halved to 250 mg and is workable for selected medium-to-large dogs, but remains coarse for small dogs and renal adjustment. Variable tablet dissolution and cation/feeding separation reduce reliability despite simple storage.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Cipro-Denk 500 SmPC2023
  2. Cipro-Denk official product2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
3.8/10
Poor / unconvincing
vetman assessment

Cipro-Denk

500 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 3.8/10 Poor / unconvincing
Evidence confidence: Medium Georgia: Yes, human · № რ-038444 · Verified on 15 Oct 2026 Off-label use

A poorly matched feline reserve presentation. Low oral bioavailability, no validated veterinary ciprofloxacin breakpoint, coarse 250-750 mg units and class retinal risk outweigh possible activity against selected Gram-negative isolates; use a better-characterised licensed alternative whenever possible.

Regulatory and scientific credibility6.0/10

This exact human tablet family has a sourced current Georgian registration, identifiable official manufacturer information and exact regulator-hosted product information, but no exact EU/EEA, GB or US registration in the checked registers. Animal use is off-label.

Clinical efficacy3.5/10

A six-cat PK study found only 33% mean oral bioavailability at 10 mg/kg twice daily and no robust clinical-outcome programme supports these tablets. Potential Gram-negative activity does not overcome uncertain exposure, lack of veterinary ciprofloxacin breakpoints, superior licensed alternatives and the need to avoid empirical treatment of feline urinary signs.

Safety and tolerability4.0/10

Cats share the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, prolonged treatment, age or impaired elimination. These coarse human tablets make peak exposure difficult to control; direct exact-product feline safety data are absent in addition to gastrointestinal, neurologic, cartilage and interaction risks.

Clinical practicality0.5/10

The validated unit for this exact 500 mg tablet is one half, still far above a typical measured feline dose. Unvalidated powder division cannot correct the mismatch; a licensed feline fluoroquinolone with an appropriate strength or suspension is substantially more controllable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Cipro-Denk 500 SmPC2023
  2. Cipro-Denk official product2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin500 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Denk Pharma · Germany
Registration
Georgia Yes, human
In force until 22 Jun 2028
Human (Ministry of Health, RAMA)
№ რ-038444
Verified on: 15 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
750 mg, Coated tablet No label dose in the reference yet - Georgia Yes, human
In force until 18 Jul 2030
Human (Ministry of Health, RAMA)
In the register: ციპრო-დენკი 750 მგ, აბი
№ რ-043647
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Cipro-Denk 750 mg, Coated tablet

film-coated tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
5.1/10
Weak evidence support
vetman assessment

Cipro-Denk

750 mg, film-coated tablet, human medicine
Assessed clinical scopeDog · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 5.1/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043647 · Verified on 16 Oct 2026 Off-label use

A weak reserve option rather than a routine veterinary fluoroquinolone. Even within this specialist-directed scope, oral tablet exposure is unpredictable and meaningful ciprofloxacin susceptibility interpretation and effective canine dosing are not established; prefer a licensed, better-characterised alternative whenever possible.

Regulatory and scientific credibility6.0/10

This exact human tablet family has a sourced current Georgian registration, identifiable official manufacturer information and exact regulator-hosted product information, but no exact EU/EEA, GB or US registration in the checked registers. Animal use is off-label.

Clinical efficacy4.0/10

Ciprofloxacin has concentration-dependent activity against selected susceptible bacteria, but current ISCAID guidance excludes oral ciprofloxacin from canine pyoderma choices: tablet absorption is low and highly variable, veterinary susceptibility breakpoints are unavailable and an effective canine dose is not established. Urinary guidance also finds it difficult to justify over approved veterinary fluoroquinolones.

Safety and tolerability5.5/10

Gastrointestinal and CNS effects, dysglycaemia, hypersensitivity, QT/tendon risks, renal clearance and drug-chelation interactions are clinically relevant; immature animals are vulnerable to quinolone arthropathy. Correctly selected adult dogs can tolerate fluoroquinolones, but exact-product veterinary safety and dosing-margin data are absent.

Clinical practicality4.5/10

The 750 mg score is only for easier swallowing and not equal-dose division. A whole tablet fits only selected large dogs, is unsuitable for precise titration or renal adjustment and retains the same formulation-dependent absorption and interaction burden.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Cipro-Denk 750 SmPC2017
  2. Cipro-Denk official product2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy
3.8/10
Poor / unconvincing
vetman assessment

Cipro-Denk

750 mg, film-coated tablet, human medicine
Assessed clinical scopeCat · Specialist-directed oral ciprofloxacin for a confirmed serious bacterial infection when lower-category and veterinary-authorised alternatives are unsuitable; not routine empirical therapy · By mouth
Care settingVeterinarian-directed treatment after sampling, with exact weight, renal and interaction review, early reassessment and culture-guided de-escalation.
vetman score 3.8/10 Poor / unconvincing
Evidence confidence: Medium Georgia: Yes, human · № რ-043647 · Verified on 16 Oct 2026 Off-label use

A poorly matched feline reserve presentation. Low oral bioavailability, no validated veterinary ciprofloxacin breakpoint, coarse 250-750 mg units and class retinal risk outweigh possible activity against selected Gram-negative isolates; use a better-characterised licensed alternative whenever possible.

Regulatory and scientific credibility6.0/10

This exact human tablet family has a sourced current Georgian registration, identifiable official manufacturer information and exact regulator-hosted product information, but no exact EU/EEA, GB or US registration in the checked registers. Animal use is off-label.

Clinical efficacy3.5/10

A six-cat PK study found only 33% mean oral bioavailability at 10 mg/kg twice daily and no robust clinical-outcome programme supports these tablets. Potential Gram-negative activity does not overcome uncertain exposure, lack of veterinary ciprofloxacin breakpoints, superior licensed alternatives and the need to avoid empirical treatment of feline urinary signs.

Safety and tolerability4.0/10

Cats share the class risk of potentially irreversible fluoroquinolone retinal degeneration, especially with high exposure, prolonged treatment, age or impaired elimination. These coarse human tablets make peak exposure difficult to control; direct exact-product feline safety data are absent in addition to gastrointestinal, neurologic, cartilage and interaction risks.

Clinical practicality0.0/10

The validated unit for this exact 750 mg tablet is one whole tablet, still far above a typical measured feline dose. Unvalidated powder division cannot correct the mismatch; a licensed feline fluoroquinolone with an appropriate strength or suspension is substantially more controllable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Fluoroquinolones are EMA AMEG Category B (Restrict). Do not use this human ciprofloxacin tablet empirically or for routine cystitis, superficial pyoderma, nonspecific diarrhoea or colonisation. Document infection, obtain diagnostic samples first and show that safer lower-category and licensed veterinary options are unsuitable.
  • No approved veterinary susceptibility breakpoint exists for ciprofloxacin and human breakpoints are inappropriate for canine isolates. A laboratory “susceptible” result alone cannot validate exposure from these tablets; consult the laboratory or a veterinary microbiology/pharmacology specialist.
  • Cats are susceptible to potentially irreversible fluoroquinolone retinal degeneration. Avoid unnecessary use; calculate from exact weight, reduce exposure with impaired renal elimination, avoid high peaks/prolonged courses and stop urgently for mydriasis, visual change or disorientation.
  • Avoid systemic ciprofloxacin in growing dogs and cats unless no safer effective alternative exists. Fluoroquinolones can damage load-bearing cartilage in immature animals; record age, growth status and the exceptional justification.
  • Stop and reassess for seizure, tremor, marked agitation, confusion, ataxia or other CNS signs. Risk can rise with epilepsy, renal accumulation and concurrent NSAIDs or other medicines that lower the seizure threshold.
  • Aluminium, magnesium, calcium, iron or zinc products, sucralfate and mineral supplements can markedly reduce oral absorption. Give ciprofloxacin at least 2 hours before or 4-6 hours after them; do not administer with dairy products or calcium-fortified drinks alone.
  • Ciprofloxacin inhibits CYP1A2. Concurrent tizanidine is contraindicated by the exact human labels; review theophylline/aminophylline, caffeine, ciclosporin, clozapine, ropinirole and vitamin-K antagonists and monitor or select another antimicrobial.
  • Review kidney function, hydration and urine output before and during treatment; adjust exposure in renal impairment and maintain hydration. Crystalluria and renal injury are uncommon but clinically important, especially with dehydration or excessive exposure.
  • Monitor for vomiting, diarrhoea, anorexia, hypersensitivity, dysglycaemia, QT-related arrhythmia, lameness, tendon pain or rupture. Stop promptly for severe allergy, persistent gastrointestinal signs, new lameness or cardiovascular collapse.
  • Use only the validated dose unit for the exact tablet. Ciprinol 250/500 and Cipro-Denk 500 can be divided into equal halves; the Cipro-Denk 750 score is only for easier swallowing and not equal dosing. Do not estimate smaller fractions or divide powder by eye.
Assessment sources
  1. Cipro-Denk 750 SmPC2017
  2. Cipro-Denk official product2026
  3. ISCAID canine pyoderma 20252025
  4. ISCAID urinary guideline 20192019
  5. EMA AMEG fluoroquinolone category2019
  6. Canine ciprofloxacin tablet PK2012
  7. Clinical canine ciprofloxacin PK2017
  8. Feline oral ciprofloxacin PK2004
  9. Feline fluoroquinolone retinopathy2002
  10. Veterinary oral formulation review2022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Ciprofloxacin750 mg
Formulation Type
Coated tablet
Administration route
By mouth
Manufacturer
Denk Pharma · Germany
Registration
Georgia Yes, human
In force until 18 Jul 2030
Human (Ministry of Health, RAMA)
In the register: ციპრო-დენკი 750 მგ, აბი
№ რ-043647
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Ciprofloxacin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25–50 mg/kg
off-label
 Dog Bacterial Infection
adults
 By mouth once daily
MSD Vet Manual 2026
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Quinolones, Including Fluoroquinolones, for Use in Animals
MSD/Merck Veterinary Manual, 2026

Known Contraindications

  • Critical
    Do not use ciprofloxacin in patients with known hypersensitivity to ciprofloxacin or another fluoroquinolone.
  • Warning
    Both ciprofloxacin and moxifloxacin have been associated with potentially fatal antimicrobial-induced colitis.
    Sources: MSD Vet Manual
  • Warning
    Avoid excessive or prolonged quinolone use in immature animals because cartilage erosion and permanent lameness have occurred in growing dogs and foals.
    Sources: MSD Vet Manual
  • Warning (Cat)
    Not well absorbed in cats
    Sources: MSD Vet Manual

Known Drug Interactions

  • Major warning Ciprofloxacin + Aminophylline
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce the aminophylline dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA
  • Major warning Theophylline + Ciprofloxacin
    Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
    Recommendation: Avoid concurrent use when possible. If the combination is unavoidable, monitor serum theophylline and reduce its dose as needed. Watch for nausea, vomiting, tremor, excitation, tachycardia, and seizures.
    Sources: FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗